|
1）Liang C, Needham M. Necrotizing autoimmune myopathy. Curr Opin Rheumatol. 2011; 23: 612-9
|
|
|
|
2）Ellis E, Ann Tan J, Lester S, et al. Necrotizing myopathy: clinicoserologic associations. Muscle Nerve. 2012; 45: 189-94
|
|
|
|
|
|
3）Miller T, Al-Lozi MT, Lopate G, et al. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry. 2002; 73: 420-8
|
|
|
|
|
|
4）Hengstman GJ, ter Laak HJ, Vree Egberts WT, et al. Anti-signal recognition particle autoanti-bodies: marker of a necrotising myopathy. Ann Rheum Dis. 2006; 65: 1635-8
|
|
|
|
|
|
5）Reeves WH, Nigam SK, Blobel G. Human autoantibodies reactive with the signal-recogni-tion particle. Proc Natl Acad Sci U S A. 1986; 83: 9507-11
|
|
|
|
|
|
6）Okada N, Mimori T, Mukai R, et al. Characteri-zation of human autoantibodies that selectively precipitate the 7SL RNA component of the signal recognition particle. J Immunol. 1987; 138: 3219-23
|
|
|
|
|
|
7）Mimori T, Imura Y, Nakashima R, et al. Autoantibodies in idiopathic inflammatory myo-pathy: an update on clinical and pathophysio-logical significance. Curr Opin Rheumatol. 2007; 19: 523-9
|
|
|
|
|
|
8）Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum. 1990; 33: 1361-70
|
|
|
|
|
|
9）Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991; 70: 360-74
|
|
|
|
|
|
10）Kao AH, Lacomis D, Lucas M, et al. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum. 2004; 50: 209-15
|
|
|
|
|
|
11）Rouster-Stevens KA, Pachman LM. Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J Rheumatol. 2008; 35: 927-9
|
|
|
|
|
|
12）Valiyil R, Casciola-Rosen L, Hong G, et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken). 2010; 62: 1328-34
|
|
|
|
|
|
13）Benveniste O, Drouot L, Jouen F, et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum. 2011; 63: 1961-71
|
|
|
|
|
|
14）Suzuki S, Hayashi YK, Kuwana M, et al. Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome. Arch Neurol. 2012; 69: 728-32
|
|
|
|
|
|
15）Dimitri D, Andre C, Roucoules J, et al. Myopathy associated with anti-signal recognition peptide antibodies: clinical heterogeneity contrasts with stereotyped histopathology. Muscle Nerve. 2007; 35: 389-95
|
|
|
|
|
|
16）Suzuki S, Satoh T, Sato S, et al. Clinical utility of anti-signal recognition particle antibody in the differential diagnosis of myopathies. Rheuma-tology (Oxford). 2008; 47: 1539-42
|
|
|
|
|
|
17）Suzuki S, Ohta M, Shimizu Y, et al. Anti-signal recognition particle myopathy in the first decade of life. Pediatr Neurol. 2011; 45: 114-6
|
|
|
|
|
|
18）Hanisch F, Muller T, Stoltenburg G, et sl. Unusual manifestations in two cases of necrotizing myopathy associated with SRP-antibodies. Clin Neurol Neurosurg. 2012 (on-line publication)
|
|
|
|
|
|
19）Matthews E, Plotz PH, Portaro S, et al. A case of necrotizing myopathy with proximal weakness and cardiomyopathy. Neurology. 2012; 78: 1527-32
|
|
|
|
|
|
20）Hegde RS, Keenan RJ. Tail-anchored membrane protein insertion into the endoplasmic reticulum. Nat Rev Mol Cell Biol. 2011; 12: 787-98
|
|
|
|
|
|
21）Romisch K, Miller FW, Dobberstein B, High S. Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages. Arthritis Res Ther. 2006; 8: R39
|
|
|
|
|
|
22）Satoh T, Okano T, Matsui T, et al. Novel autoantibodies against 7SL RNA in patients with polymyositis/dermatomyositis. J Rheumatol. 2005; 32: 1727-33
|
|
|
|
|
|
23）Zampieri S, Ghirardello A, Iaccarino L, et al. Anti-Jo-1 antibodies. Autoimmunity. 2005; 38: 73-8
|
|
|
|
|
|
24）Hamaguchi Y, Kuwana M, Hoshino K, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011; 147: 391-8
|
|
|
|
|
|
25）Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011; 63: 713-21
|
|
|
|
|
|
26）Pestronk A. Acquired immune and inflammatory myopathies: pathologic classification. Curr Opin Rheumatol. 2011; 23: 595-604
|
|
|
|
|
|
27）三輪道然，中村由紀，長坂高村，他．筋萎縮が頸筋と上肢帯にほぼ限局してみとめられた抗SRP抗体多発筋炎の1例．臨床神経．2012; 52: 234-8
|
|
|
|
|
28）Arlet JB, Dimitri D, Pagnoux C, et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord. 2006; 16: 334-6
|
|
|
|
|